|Multibagger Potential in 2 years ?? doesn't kill healthy cells in cancer|
1. VSAR Director bought 1,055,485 shares at $1.74-2.00 worth ~ $2 mln
2. Why leave a Big Pharma like Astellas, and after a career in Big Pharmas, and move to a relatively unknown, new-look upstart that isn’t yet in the clinic? For an answer to that question, he went back to the beginning at the Japanese pharma. “When I went to Astellas, they were just starting to really make a move into oncology; that’s why I was brought in—to basically help create an oncology program that wasn’t there before."
“Not everything we worked on was successful, but I think we created a pretty solid program in oncology. Now, when you’re in a company like Astellas, you look internally, but you’re also looking outside for new and great ideas; you can’t invent everything in-house. So, one of the companies we were looking at was Ruga. We liked the science, but it wasn’t a good strategic fit for Astellas; they wanted something later-stage, so a deal was never made.”
Something about that company remained with Eck. “I thought what they were doing was really cool. And I got to know the team [including Ray Tabibiazar, M.D., founding president and CEO of Aravive/Ruga, and now chair]."
“So, I was a big fan of this small company; and one day, Ray called me up and said you have a lot of experience in cancer, do you want to run the company? I said yeah! Sign me up. It was an easy decision,” he added.
3. PRESENTATION LINK